Autonomix Medical (NASDAQ:AMIX – Get Free Report) and Becton, Dickinson and Company (NYSE:BDX – Get Free Report) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, institutional ownership, valuation, profitability, analyst recommendations, earnings and dividends.
Profitability
This table compares Autonomix Medical and Becton, Dickinson and Company’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Autonomix Medical | N/A | -542.11% | -236.92% |
| Becton, Dickinson and Company | 8.55% | 14.89% | 6.98% |
Earnings and Valuation
This table compares Autonomix Medical and Becton, Dickinson and Company”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Autonomix Medical | N/A | N/A | -$15.43 million | ($16.07) | -0.19 |
| Becton, Dickinson and Company | $20.18 billion | 3.50 | $1.71 billion | $5.94 | 41.02 |
Analyst Recommendations
This is a summary of recent ratings and recommmendations for Autonomix Medical and Becton, Dickinson and Company, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Autonomix Medical | 0 | 0 | 1 | 0 | 3.00 |
| Becton, Dickinson and Company | 0 | 0 | 6 | 0 | 3.00 |
Autonomix Medical currently has a consensus target price of $28.00, indicating a potential upside of 806.15%. Becton, Dickinson and Company has a consensus target price of $283.50, indicating a potential upside of 16.34%. Given Autonomix Medical’s higher probable upside, equities research analysts plainly believe Autonomix Medical is more favorable than Becton, Dickinson and Company.
Insider & Institutional Ownership
10.8% of Autonomix Medical shares are held by institutional investors. Comparatively, 87.0% of Becton, Dickinson and Company shares are held by institutional investors. 32.4% of Autonomix Medical shares are held by company insiders. Comparatively, 0.4% of Becton, Dickinson and Company shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Summary
Becton, Dickinson and Company beats Autonomix Medical on 9 of the 11 factors compared between the two stocks.
About Autonomix Medical
Autonomix Medical, Inc., a development stage medical device development company, focuses on advancing technologies for sensing and treating disorders relating to the peripheral nervous system. Its technology platform includes a catheter-based microchip-enabled sensing array to detect and differentiate peripheral neural signals. The company was incorporated in 2014 and is based in The Woodlands, Texas.
About Becton, Dickinson and Company
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; and prefillable drug delivery systems. The BD Life Sciences segment offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The BD Interventional segment provides hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.
Receive News & Ratings for Autonomix Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Autonomix Medical and related companies with MarketBeat.com's FREE daily email newsletter.
